Alnylam Pharmaceuticals, Inc. (ALNY) Posts Quarterly Earnings Results, Misses Estimates By $0.12 EPS
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.22) by $0.12, Bloomberg Earnings reports. Alnylam Pharmaceuticals had a negative return on equity of 42.90% and a negative net margin of 705.11%. The company had revenue of $15.93 million for the quarter, compared to the consensus estimate of $23.86 million. During the same quarter in the previous year, the firm posted ($1.05) EPS. The business’s revenue for the quarter was up 82.9% compared to the same quarter last year.
Shares of Alnylam Pharmaceuticals (ALNY) traded down 4.3163% during mid-day trading on Thursday, reaching $77.0445. 142,386 shares of the company’s stock traded hands. Alnylam Pharmaceuticals has a 12 month low of $31.38 and a 12 month high of $86.92. The firm has a 50 day moving average price of $81.35 and a 200-day moving average price of $61.53. The stock’s market cap is $6.64 billion.
Several research firms have recently issued reports on ALNY. Morgan Stanley restated an “equal weight” rating on shares of Alnylam Pharmaceuticals in a report on Monday, July 10th. Chardan Capital set a $95.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, May 5th. BMO Capital Markets began coverage on shares of Alnylam Pharmaceuticals in a report on Monday, April 17th. They set an “outperform” rating and a $73.00 price objective on the stock. Ladenburg Thalmann Financial Services set a $80.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, May 17th. Finally, Vetr cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 target price on the stock. in a research note on Monday, May 15th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $79.79.
ILLEGAL ACTIVITY NOTICE: This report was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.watchlistnews.com/alnylam-pharmaceuticals-inc-nasdaqalny-releases-quarterly-earnings-results-beats-estimates-by-0-15-eps/1466808.html.
In other Alnylam Pharmaceuticals news, EVP Akshay Vaishnaw sold 11,000 shares of the firm’s stock in a transaction dated Tuesday, May 23rd. The shares were sold at an average price of $75.00, for a total value of $825,000.00. Following the transaction, the executive vice president now directly owns 21,297 shares of the company’s stock, valued at approximately $1,597,275. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Laurie Keating bought 11,500 shares of the firm’s stock in a transaction on Tuesday, May 30th. The stock was purchased at an average cost of $65.35 per share, for a total transaction of $751,525.00. Following the completion of the acquisition, the senior vice president now owns 11,500 shares in the company, valued at $751,525. The disclosure for this purchase can be found here. Over the last three months, insiders sold 64,125 shares of company stock worth $4,325,000. Insiders own 4.30% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. First Manhattan Co. purchased a new position in Alnylam Pharmaceuticals during the first quarter valued at approximately $135,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Alnylam Pharmaceuticals during the first quarter valued at approximately $148,000. Westpac Banking Corp purchased a new position in Alnylam Pharmaceuticals during the first quarter valued at approximately $202,000. Prudential Financial Inc. purchased a new position in Alnylam Pharmaceuticals during the first quarter valued at approximately $215,000. Finally, CIBC Asset Management Inc purchased a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $221,000. 88.96% of the stock is currently owned by hedge funds and other institutional investors.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.